|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Anti-Cancer(Oncology) Agents
|
CI-994(Tacedinaline)
| Catalogue No. : |
C13487 |
| Product Name: |
CI-994(Tacedinaline) |
| Synonym: |
N-acetyldinaline;Acetyldinaline;CI 994;Tacedinaline;PD-123654;PD 123654;Goe 5549 |
| Chemical Name: |
4-(Acetylamino)-N-(2-aminophenyl)benzamide |
| CAS No. : |
112522-64-2 |
| Structure : |
|
| Molecular Formula: |
C15H15N3O2 |
| Molecular Weight: |
269.3 |
| Purity: |
>98% |
| Usage: |
CI-994 is the acetylated derivative form of the original compound Dinaline (PD 104 208). It is an oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. It is used for combination therapy for selected tumors including non-small cell lung, pancreatic, breast, and colorectal cancers. It acts as a histone deacetylase inhibitor. CI-994 blocks cells in the G1-S phase of the cell cycle. The 16 kDa phosphoprotein is confined to the nuclear compartment. Loss of the 16-kDa nuclear phosphoprotein appears to be a direct effect of CI-994 treatment and that the inhibition of this phosphoprotein may play a critical role in the mechanism of action of CI-994. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
